VAXCYTE, INC. Payments of Stock Issuance Costs
VAXCYTE, INC. (PCVX) reported Payments of Stock Issuance Costs of $3.37 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-02-27
- VAXCYTE, INC. payments of stock issuance costs for the quarter ending 2020-12-31 was $0.00.
- VAXCYTE, INC. payments of stock issuance costs for the quarter ending 2020-09-30 was $72.00K.
- VAXCYTE, INC. payments of stock issuance costs for fiscal 2020 was $3.37M.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 1 month as first filed | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $72.00K derived: sum of 2 quarters · filed 2022-02-28 | $3.37M 10-K · filed 2022-02-28 | ||||
| 2020-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $3.37M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $3.40M 10-K · filed 2023-02-27 | $3.30M 10-Q · filed 2020-08-12 | $3.30M 10-Q · filed 2021-08-11 | ||||
| 2020-06-11 | $3.40M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |